A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design,
umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with
breast cancer.